Changes in Microbiota and Metabolites Are Associated With Effects of Bile Acid Sequestrant on Icteric Primary Biliary Cholangitis
Xiong Ma,Bo Li,Jun Zhang,Yong Chen,Qixia Wang,Li Yan,Rui Wang,Yiran Wei,Z. You,Yikang Li,Qing Miao,Xiao Xiao,M. Lian,Weihua Chen,D. Qiu,Jingyuan Fang,M. Gershwin,R. Tang
DOI: https://doi.org/10.21203/rs.3.rs-76953/v1
2020-09-17
Abstract:
BackgroundIncreasing data suggests an interaction between bile acids (BAs) and intestinal microbiota in the pathogenesis of primary biliary cholangitis (PBC). Bile acid sequestrants are widely used to bind BA in the intestinal lumen and therefore are posited to impact gut bacteria. Herein we aimed to investigate the effects of cholestyramine on the BA profile and gut microbiome in a cohort of icteric PBC patients. Results Thirty-three PBC patients were treated with cholestyramine and serum and stool samples were collected at baseline, 4 and 16 weeks. Shotgun metagenomic sequencing, targeted metabolomic profiling were performed. Following cholestyramine administration, patients exhibited a high inter-personal variability in remission of cholestasis, and were therefore dichotomized according to the decrease of total bilirubin. In general, BA profiling revealed a shift toward a more hydrophilic milieu, along with decreased circulating fibroblast growth factor 19 and increased active glucagon-like peptide 1. Gut microbial co-abundance networks showed distinct taxa interactions in subjects with superior remission (SR) and those with inferior remission (IR) at baseline. Compositional shifts of the microbiome in SR group were characterized with enrichment of two Lachnospiraceae species, typically producing short-chain fatty acids (SCFAs). In contrast, Klebsiella pneumonia, a commensal pathobiont, was only increased in IR group. Correspondingly, patients with SR, but not IR, were marked by elevations of SCFAs including valeric acid and caproic acid. Finally, integrative analysis identified robust associations between the variations of microbiota, metabolites, and inflammatory cytokines in SR group, indicating potential mechanistic links.ConclusionsBeneficial responses caused by cholestyramine were closely related with compositional and functional alterations in gut commensal, highlighting the possibility of exploring bile acids-microbiota interactions for treating PBC.
Chemistry